Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of specific share plan transactions and does not contain financial performance data.
Material Changes
No material changes to financial performance or business operations are reported in this filing. The document details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) on May 10, 2012, at a price of $45.50 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) regarding the specific transactions listed below:
- Dr M M Slaoui: 11 ADSs (Connected Person: Dr K Slaoui, 9 ADSs)
- Mr W C Louv: 16 ADSs
- Dr D Pulman: 29 ADSs
- Mr E J Gray: 21 ADSs
- Mrs D P Connelly: 1 ADS
Investor Verification Checklist
- Verify the impact of the US Retirement Savings Plan revaluation on total insider holdings.
- Confirm the transaction price of $45.50 per ADS against market data for May 10, 2012.
- Review the full list of directors and PDMRs to ensure all required disclosures were made under Rule 3.1.4R.
- Note that this filing does not replace or update the company's financial results; refer to Form 20-F for financial metrics.